About Us

As a Swiss pharmaceutical company headquartered in Zurich, we develop, manufacture and internationally market well-proven and innovative pharmaceuticals in novel drug delivery forms.

We are a leader in advanced drug delivery technologies with a focus on modified release oral forms, and oral dispersible forms, for which we also hold patents.

With a clear focus on selected markets in the Middle East, Africa, the CIS Region, and Latin America, we are operating in some of the most dynamic countries of the world. Our in-depth knowledge of our markets enables us to adapt to local needs, however challenging.

We make and provide quality medicines having patients in mind. We are dynamic and open-minded – we seize opportunities and stay strong, even if it gets difficult.

That’s how we really make a difference. And that is the spirit we bring to all our fields of business.

Key Figures

  • Group sales

    €325m

    As of December 31, 2015

  • Annual Growth 2015

    +20%

    As of December 31, 2015

  • Employees1

    >1,600

    As of June 30, 2016

  • Manufacturing sites1

    5

    Switzerland (3), Ukraine and Estonia

  • Regional offices

    4

    Kiev, Dubai, Panama and Moscow

  • Sales offices

    3

    Abidjan, Cairo and Almaty

1. Taking into account the agreement signed between Acino International AG and Acino Pharma AG to divest Acino’s transdermal patch and implant business to Luye Pharma Group Ltd.